"CA125/MUC16 jako diagnostick\u00FD a prognostick\u00FD marker pro karcinom ovaria" . "1802-4475" . "CZ - \u010Cesk\u00E1 republika" . . . "Onkologie" . "CA125/MUC16 jako diagnostick\u00FD a prognostick\u00FD marker pro karcinom ovaria"@cs . "CA125/MUC16 jako diagnostick\u00FD a prognostick\u00FD marker pro karcinom ovaria" . . "ovarian cancer; diagnostics; treatment; CA125; HE4; RECAF"@en . "2" . "The most fatal gynecologic malignancy, ovarian cancer, causes more than 50% deaths in this tumor group. Most of cases (>60%) are di- agnosed in advanced stages with poor 5-year survival prognosis. Diagnostic tools for an effective early detection or screening have not been found yet. Treatment possibilities (surgery, chemotherapy) are insufficient while high tendency to recurrence and chemoresistance occurs. CA125/MUC16 has been one of the most extensively used markers for a detection of primary tumors, or recurrence for a long time since its discovery in 80s. However, the structure and biological functions of CA125 have been discovered relatively recently. CA125 may play an important role in carcinogenesis and interactions with cells of immune system. We reviewed the known biological functions and particularly the current state of using this marker as the diagnostic tool in ovarian cancer. Recently, many new markers emerged ambitiously to replace CA125; moreover, the importance of monitoring CA125 for the recurrence detection has also been questioned in large clinical trials. These studies have not found an impact for overall survival/mortality of patients. Also a potential of using CA125 targeted antibodies has not brought previously expected results so far."@en . . "CA125/MUC16 jako diagnostick\u00FD a prognostick\u00FD marker pro karcinom ovaria"@cs . . . "126155" . "1"^^ . . . "http://solen.cz/pdfs/xon/2012/02/04.pdf" . "CA125/MUC16 in diagnosis and prognosis of ovarian cancer"@en . "[92D2326DE507]" . . . . "Z\u00E1vesk\u00FD, Lud\u011Bk" . . "1"^^ . "6" . "RIV/00064165:_____/12:11608!RIV13-MZ0-00064165" . "I" . . . "Nejzhoubn\u011Bj\u0161\u00ED gynekologick\u00FD n\u00E1dor, karcinom ovaria, je p\u0159\u00ED\u010Dinou v\u00EDce ne\u017E 50 % \u00FAmrt\u00ED v t\u00E9to skupin\u011B n\u00E1dor\u016F. V\u00EDce ne\u017E 60 % p\u0159\u00EDpad\u016F je diagnostikov\u00E1no a\u017E v pokro\u010Dil\u00FDch stadi\u00EDch s v\u00FDrazn\u011B sn\u00ED\u017Eenou pravd\u011Bpodobnost\u00ED p\u0159e\u017Eit\u00ED pacientek. Diagnostick\u00E9 n\u00E1stroje pro efektivn\u00ED \u010Dasnou detekci nebo screening zat\u00EDm neexistuj\u00ED. Terapeutick\u00E9 mo\u017Enosti (chirurgick\u00E1 operace, chemoterapie) jsou nedostate\u010Dn\u011B efektivn\u00ED, nebo\u0165 karcinom ovaria se vyzna\u010Duje silnou tendenc\u00ED k recidiv\u011B spojenou s chemorezistenc\u00ED. Jedn\u00EDm z nejd\u00E9le a nejrozs\u00E1hleji pou\u017E\u00EDva- n\u00FDm markerem pro diagnostiku prim\u00E1rn\u00EDch n\u00E1dor\u016F i recidivy je CA125/MUC16. Tento glykoprotein je zn\u00E1m ji\u017E od 80. let 20. stolet\u00ED, ale teprve nejnov\u011Bj\u0161\u00ED studie odhaluj\u00ED jeho biologick\u00E9 funkce v karcinogenezi a interakc\u00EDch s bu\u0148kami imunitn\u00EDho syst\u00E9mu. V tomto \u010Dl\u00E1nku se bl\u00ED\u017Ee pod\u00EDv\u00E1me na jeho biologick\u00FD v\u00FDznam a p\u0159edev\u0161\u00EDm na sou\u010Dasn\u00FD stav pou\u017Eit\u00ED CA125 jako v\u00FDznamn\u00E9ho diagnostick\u00E9ho markeru u karcinomu ovaria. V diagnostice prim\u00E1rn\u00EDch n\u00E1dor\u016F se toti\u017E za\u010D\u00EDnaj\u00ED objevovat nov\u00E9 markery, nav\u00EDc je v\u00FDznam monitoringu CA125 z hlediska detekce recidivy zpochyb\u0148ov\u00E1n rozs\u00E1hl\u00FDmi klinick\u00FDmi studiemi, kter\u00E9 nenalezly p\u0159\u00EDnos pro dlouhodob\u00E9 p\u0159e\u017Eit\u00ED pacientek. Tak\u00E9 potenci\u00E1ln\u00ED v\u00FDznam CA125 v imunoterapii karcinomu ovaria se nezd\u00E1 b\u00FDt tak velk\u00FD, jak se p\u0159edpokl\u00E1dalo." . "CA125/MUC16 in diagnosis and prognosis of ovarian cancer"@en . . . "RIV/00064165:_____/12:11608" . "Nejzhoubn\u011Bj\u0161\u00ED gynekologick\u00FD n\u00E1dor, karcinom ovaria, je p\u0159\u00ED\u010Dinou v\u00EDce ne\u017E 50 % \u00FAmrt\u00ED v t\u00E9to skupin\u011B n\u00E1dor\u016F. V\u00EDce ne\u017E 60 % p\u0159\u00EDpad\u016F je diagnostikov\u00E1no a\u017E v pokro\u010Dil\u00FDch stadi\u00EDch s v\u00FDrazn\u011B sn\u00ED\u017Eenou pravd\u011Bpodobnost\u00ED p\u0159e\u017Eit\u00ED pacientek. Diagnostick\u00E9 n\u00E1stroje pro efektivn\u00ED \u010Dasnou detekci nebo screening zat\u00EDm neexistuj\u00ED. Terapeutick\u00E9 mo\u017Enosti (chirurgick\u00E1 operace, chemoterapie) jsou nedostate\u010Dn\u011B efektivn\u00ED, nebo\u0165 karcinom ovaria se vyzna\u010Duje silnou tendenc\u00ED k recidiv\u011B spojenou s chemorezistenc\u00ED. Jedn\u00EDm z nejd\u00E9le a nejrozs\u00E1hleji pou\u017E\u00EDva- n\u00FDm markerem pro diagnostiku prim\u00E1rn\u00EDch n\u00E1dor\u016F i recidivy je CA125/MUC16. Tento glykoprotein je zn\u00E1m ji\u017E od 80. let 20. stolet\u00ED, ale teprve nejnov\u011Bj\u0161\u00ED studie odhaluj\u00ED jeho biologick\u00E9 funkce v karcinogenezi a interakc\u00EDch s bu\u0148kami imunitn\u00EDho syst\u00E9mu. V tomto \u010Dl\u00E1nku se bl\u00ED\u017Ee pod\u00EDv\u00E1me na jeho biologick\u00FD v\u00FDznam a p\u0159edev\u0161\u00EDm na sou\u010Dasn\u00FD stav pou\u017Eit\u00ED CA125 jako v\u00FDznamn\u00E9ho diagnostick\u00E9ho markeru u karcinomu ovaria. V diagnostice prim\u00E1rn\u00EDch n\u00E1dor\u016F se toti\u017E za\u010D\u00EDnaj\u00ED objevovat nov\u00E9 markery, nav\u00EDc je v\u00FDznam monitoringu CA125 z hlediska detekce recidivy zpochyb\u0148ov\u00E1n rozs\u00E1hl\u00FDmi klinick\u00FDmi studiemi, kter\u00E9 nenalezly p\u0159\u00EDnos pro dlouhodob\u00E9 p\u0159e\u017Eit\u00ED pacientek. Tak\u00E9 potenci\u00E1ln\u00ED v\u00FDznam CA125 v imunoterapii karcinomu ovaria se nezd\u00E1 b\u00FDt tak velk\u00FD, jak se p\u0159edpokl\u00E1dalo."@cs . . . "3"^^ .